Full Press Release Details
begin, I would like to mention our Safe Harbor Statement. Statements
in this announcement, other than historical data and information, constitute
"forward-looking statements", and involve risks and uncertainties, that could
cause BrainStorm Cell Therapeutics' actual results, to differ materially, from
those stated or implied, by such forward-looking statements. The potential risks
and uncertainties, include, risks associated with BrainStorm's limited operating
history, history of losses, minimal working capital, dependence on its license
to Ramot's technology, ability to adequately protect the technology, dependence
on key executives and on its scientific consultants, ability to obtain required
regulatory approvals, and other factors, detailed in BrainStorm's annual report
on Form 10-K, and quarterly reports on Form 10-Q, available at
http://www.sec.gov. The Company does not undertake any obligation, to update
forward-looking statements made by us.
now like to turn the call over to BrainStorm's CEO, Rami Efrati.
begin addressing some of the questions, I would like to give a little background
on the Company, for the benefit of those new to BrainStorm.
is a US public bio-technology company, traded on the Over-the-Counter
Bulletin Board under the ticker symbol BCLI. BrainStorm's operations are located
in Israel. Established in 2004, BrainStorm is developing, innovative adult stem
cell therapies, for highly debilitating, neurodegenerative disorders, such as,
Amyotrophic Lateral Sclerosis, known as ALS, or Lou Gehrig's disease, and
Parkinson's Disease, areas of currently unmet clinical need.
novel autologous stem cell-therapy, seeks to repair and support degenerated
tissues, by processing adult human bone marrow mesenchymal stem cells, inducing
them to differentiate into supportive neurological cells, and transplanting the
cells back into the site of damage. Autologous transplantation of stem cells,
should result, in a safe and effective therapy, with minimal risk of rejection,
free of controversy, or ethical issues.
patent pending technology is based on discoveries made by the scientific team,
led by Professor Eldad Melamed, former Head of Neurology, at Rabin Medical
Center, and cell biologist Professor Daniel Offen, Head of the Neuroscience
Laboratory, at the Felsenstein Medical Research Center, of Tel-Aviv University.
The technology allows for the differentiation of bone marrow-derived stem cells
into functional neurons and astrocytes, as demonstrated in animal
Company holds rights to develop and commercialize the technology through an
exclusive, worldwide licensing agreement, with Ramot at Tel Aviv University, the
technology transfer company of Tel-Aviv University. The Company's current focus
is on ALS, although its technology has promise for treating several other
diseases, including Parkinson's Disease, Multiple Sclerosis, spinal cord
injuries, Huntington's disease and stroke.
will you please ask our first question.
the human clinical studies will be performed in three phases. In
Phase I, we will test for safety; in Phase II, we will test for efficacy, in a
small controlled group; and in Phase III, will test for efficacy in a large
our original estimation, we anticipated that we would begin clinical trials
towards the end of 2010.
in parallel to this plan, the Company is now proceeding with a plan that may
significantly shorten the process, and should result in being able to commence
clinical trials, at an earlier date. If we are successful in this
process, we will notify our shareholders.
the recruitment of patients for the clinical trials, we will announce our policy
once we have reached that stage.
have announced in our press releases, our science, technology and treatment have
been shown to be effective in studies performed on models of Parkinson's
Disease, Multiple Sclerosis, Huntington disease, spinal cord injury and
stroke. We believe that our technology will work, and help people
suffering from these diseases. When we obtain additional funding, we will
continue our work towards clinical trials for these diseases as
and have a good day.